Meet our mentors
Mentors 2015
Americas Mentors
Jens Eckstein
President, SR One + more
I came to SR One from TVM Capital where I was a Venture Partner, Entrepreneur-in-Residence and appointed CEO and President of SelectX Pharmaceuticals. Prior to that, I was a General Partner in TVMs Boston life sciences practice where I focused on earlier-stage investments. I am currently Chairman of the Board of Directors of Thrasos Therapeutics and a Director at Alios BioSciences. I was also the founder of Akikoa Pharmaceuticals, a biotechnology start-up company focusing on hearing loss, and North Haven Systems, a life science IT company.
Ilan Zipkin
Senior Investment Director at Takeda Ventures, Inc. + more
I have been involved in biotechnology and pharmaceutical venture capital since 2000. Previously I was a Partner at the institutional venture firms Prospect Venture Partners and MPM Capital, where I focused on investments in therapeutics companies as well as platform technologies. In addition to serving on the Board of several private and public biotechnology companies, I served as the CEO of Chimeros, Inc., a protein-based system for the development of multivalent biologic therapeutics.
Thomas Luby
Senior Director, New Ventures, Johnson & Johnson Innovation, Boston + more
I focus primarily on cardiovascular & metabolic; infectious diseases and vaccines; and neurobiology. Prior to joining Johnson & Johnson, I was Senior Director of Research Ventures at Shire Human Genetic Therapies.
Cayce Denton
Vice President, TPG Biotech + more
Prior to joining TPG Biotech in 2010, I managed finance for the Nutropin and Lytics franchises at Genentech, Inc., where I also participated in a CFO Rotation Program consisting of time in R&D Finance, Financial Planning and Analysis, Audit and Treasury. Prior to Genentech, Inc., I was in Business Development at Novartis in Cambridge, where she helped execute an approximately $700 million partnership with Alnylam Pharmaceuticals, Inc.
Tamara Rajah
Partner, McKinsey & Company + more
At McKinsey, I am a leader of the Firm's work on innovation and entrepreneurship. I focus on growing life sciences, technology and digital clusters and work extensively with start-ups, investors, government, academia and industry in these geographies.
Brian Gallagher
Partner, SR One + more
I established the SR One Boston office in 2010 and am focused on building innovative therapeutic and life science companies. I previously led the firm's investments in Dicerna Pharmaceuticals (NASDAQ: DRNA) and SpringLeaf Therapeutics. I have over 15 years of investing, business development, operational, and R&D experience in both biotechnology and large pharma companies.
Sutanto Widjaja
Portfolio Manager, Symphony Asset Management + more
I have over 10 years of Healthcare Investment experience and I'm a Co-Founder of Sutro Biopharma (funded by SV Life Sciences, Alta Partners, Skyline Ventures, Amgen Ventures, Lilly Ventures and Celgene) and Manager at WineShopper.com (funded by Kleiner).
Jill Carroll
Senior Associate, SR One + more
I joined SR One in 2011 with a background in biotech partnering and commercial development. Prior to SR One, I was responsible for Corporate Development at Dynavax Technologies, where I was involved in multiple pharma partnering deals as well as substantial private and public financings. Previously, I was a consultant specializing in health care at Clearview Projects and Mercer Management Consulting.
Simeon J. George
Partner, SR One + more
I lead SR One's investment activities on the West Coast. Prior to joining SR One, I was a consultant at Bain & Company and an investment banker at Goldman Sachs and Merrill Lynch.
Vikas Goyal
Associate, SR One + more
I joined SR One in January 2011, after interning with SR One since 2009. Prior to joining SR One, I was a consultant at McKinsey & Co, a co-founder of Extera Partners, and a business development manager at Infinity Pharmaceuticals. Over my career, I have supported business and corporate development activities for nearly 50 large and small public, venture-backed, and angel funded life science companies.
Jeff Calcagno
New Ventures, Johnson & Johnson Innovation, California + more
I helped to establish the California Innovation Center. He also worked for 18 months making and managing venture investments for Johnson & Johnson. As a licensed physician, I have over two decades of diversified healthcare and business experience: as a senior operating executive, business development professional, venture investor, entrepreneur, and clinician.
Lesley Stolz
Director, Transactions, Johnson & Johnson Innovation, California + more
I have been working in corporate and business development roles for the last 17 years for companies that are both technology platform and therapeutics focused. My most recent executive positions have been with BioTime, a publicly traded stem cell technology and therapeutic company, and Sutro Biopharma, a platform technology company working in cell-free protein synthesis.
Marian Nakada
Vice President, Venture Investments, Johnson & Johnson Innovation – JJDC + more
I am based in the Johnson & Johnson Innovation Center in Boston. I focus primarily on pharmaceuticals (small molecules and biologics) and diagnostics. Previously, I was Vice President of Strategy & Operations and External Innovation for Johnson & Johnson’s Biotechnology CoE, where I helped to drive the development and execution of the biotechnology strategy across Janssen R & D.
Michelle Browner
Senior Director, Platform Innovation & Partnership Management, Johnson & Johnson Innovation, Boston + more
I am Senior Director of Platform Innovation and Partnership Management at Johnson & Johnson Innovation, Boston. Previously, I was CEO of Enlight Biosciences, a unique entrepreneurial partnership with major pharmaceutical companies and leading academic researchers, focused on building companies based on breakthrough innovations for drug discovery and development.
Partha Ray
Director, Surgical Innovation, Johnson & Johnson Innovation, California + more
I am a medical technology professional with track record of bringing innovative technologies to market and maximizing their business potential. I have experience with product management, market assessment, care delivery, reimbursement, regulatory and quality systems.
Sarah Bodary
Senior Director, New Ventures - Oncology, Johnson & Johnson Innovation, California + more
I am experienced in drug and business development as well as company creation and venture investing. Prior to joining Johnson & Johnson Innovation, I was a Venture Partner as SV Life Sciences where as a member of the therapeutic investing team, I was involved in evaluating investment opportunities, starting Arsanis Biosciences and served on the board of Itero Biopharmaceuticals.
Stacy Feld
Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation, California + more
I lead Consumer sector efforts to identify, nurture, and on-board technical and strategic value assets, and identify potential synergies. I have nearly two decades of diverse experience in the healthcare, life sciences and consumer sectors as a transactional attorney, business development executive, venture investor and business strategist.
Stephanie Robertson
Director, New Ventures and Partnerships, Johnson & Johnson Innovation, California + more
I bring expertise in drug discovery and early clinical development, as well as business development and alliance management, to the New Ventures team at Johnson & Johnson’s California Innovation Center. I previously led business development efforts for UCSF and built one of the first formal alliance management teams found in an academic setting. Prior to joining UCSF, I worked for over a decade at Exelixis, Inc., during which the company grew from early start-up to over 700 employees.
Ken Colley
Medical Director, Translational and Integrative Medicine at BioVasc Inc. + more
Dr. Kenneth J. Colley, MD, PhD, is an accomplished physician-­‐scientist-­‐entrepreneur with  two  decades  experience  in  clinical  medicine,  pharmaceutical  product  development,  the biotech/medtech/nutratech industries, and startups formation and funding. Ken is currently  and  since  2012  a  consulting  Medical  Director  at  Theravance  BioPharma,  a publically-­‐traded biopharma company (TBPH), and most recently from 2009-­‐2011 was Medical Director at diaDexus Inc., a publically-­‐traded cardiovascular biotech company, also based in South San Francisco. Prior to that he was VP Product Development at Medlogics Device  Corporation,  a  cardiovascular  pharma-­‐medtech  firm  focused  on  interventional  cardiology and next generation DES, where he was responsible for pharmaceutical R&D, preclinical and clinical aspects of Medlogics' product development. He joined Medlogics in 2004 as the lead Science and Technology officer concurrent with its deal acquiring certain assets  of  BioVasc  Inc.,  an  emerging  medtech/biotech  company  developing  cardiovascular  products at the convergence of biopharmaceuticals and medical devices, which he founded in 2003. Prior to that Ken served as VP Product Development for start-­‐up orthobiologics company OsteoGenix Inc. (acquired by Medtronic orthobiologics unit), while serving on the development team at Shalon Ventures in Palo Alto. Dr. Colley was formerly the founding CEO and medical and technology director of Angiogenix Inc., raising over $20 million from start-­‐up in 1998 through early clinical trial phases prior to his departure to form BioVasc in 2003. Prior to Angiogenix, Dr. Colley designed advanced drug delivery systems at Cygnus Inc.   He  received  his  M.D.  from  Georgetown  University,  subsequently  training  in  Internal  Medicine at Johns Hopkins University, and also received his Ph.D. in Molecular Pharmacology  from  Georgetown  University.   He  holds  a  B.S.  in  Biological  Sciences  with  a  product design engineering minor from Stanford University.
Simon Greenwood
Genentech Investment Director, Roche Venture Fund + more
I am an investment director for the Roche Venture Fund with more than 15 years of experience in the biotechnology industry. In this role, I have led investments in companies such as Allakos, Biodesy, CytomX, DVS (acquired by Fluidigm), Epic Sciences, Maculogix and Stratos. Prior to his role at the Roche Venture Fund, I was the head of GenenFund, Genentech’s corporate venture fund.
Neil Berkley
Executive Director of Business Development - West Coast, GSK + more
I recently joined GSK, after having worked in business development roles at Cadence Pharmaceuticals and Mpex Pharmaceuticals.
Daina Graybosch
Associate Principal, McKinsey & Company + more
I joined McKinsey in 2007 after completing at Ph.D. in Structural Biology and Biochemistry at Harvard University.
Eric Soller
Engagement Manager, McKinsey & Company + more
I am a member of the PMP (Pharmaceutical and Medical Products) practice and Corporate Finance Practice and Transactions service line with focus on Healthcare-related transactions. I have led life science engagements across US, Europe and the Middle East.
Katherine Miller
Engagement Manager at McKinsey & Company + more
I am an Engagement Manager at McKinsey & Company. Previously I worked as a lead national content developer at The Princeton Review. I am a PhD graduate in Biophysics from University of California, Berkeley.
Dennis He
VP Life Sciences, Silicon Valley Bank + more
I am based in San Francisco and I focus on biopharma and diagnostics. Prior to joining Silicon Valley Bank, I was Portfolio Manager, Technology and Life Sciences at East West Bank.
Jaione Maiz
Analytics Valuations Associate, Life Science Specialist, Silicon Valley Bank + more
I joined Silicon Valley Bank in 2013, after an internship at venBio. This is my second year of being involved in OneStart.
Julie Betts
Advisor, Silicon Valley Bank Analytics + more
I am an Advisor in the Analytics team at Silicon Valley Bank in San Francisco and I'm building out our advisory practice for valuations of early-stage companies, acquisitions for large firms, as well as bench marking.
Stefan Engst
Principal Scientist, Cytokinetics + more
I am a Principal Scientist with extensive multidisciplinary experience in drug discovery and candidate selection. I have advised executive management and key senior staff, establishing scientific guidance and ongoing strategic planning for oncology, metabolic and muscular disease projects.
Danny Janiak
Partner, Mercury Fund + more
I focus on new company creation and early-stage investment opportunities in the life sciences. Prior to joining Mercury, I was an Associate in the Physical and Biological Technologies practice at In-Q-Tel, the strategic venture investment arm of the U.S. Intelligence Community.
Adriana Tajonar
Entrepreneurship Program Manager, QB3 + more
I manage the QB3 Startup in a Box and QB3 Accelerator programs, a core part of QB3’s initiative to launch life science companies and set them up for operational success. I also run the QB3-BayBio Accelerator Program, which aims to make companies operationally efficient by providing advice, checklists, and connections to best-in-class service providers.
Douglas Crawford
Associate Director, QB3 & Managing Director, Mission Bay Capital + more
My goal is to help entrepreneurial scientists create successful startups to meet California’s needs for better health, a sustainable environment, and economic growth—particularly jobs. To this end, my colleagues at QB3 and I have systematically lowered the barriers between great ideas and successful companies. I am also a founder and managing director of Mission Bay Capital, an $11.3M seed-stage venture fund that makes pivotal early-stage investments in bioscience companies.
Neena Kadaba
Director of Industry Alliances, QB3 + more
I work to initiate new collaborations between industry and QB3 campus scientists and manages QB3’s multi-year, multimillion dollar alliance with Pfizer. Previously, I co-founded Cypress Innovations and was an associate and Kauffman Fellow in the venture capital group at Itochu Technology.
Richard Yu
Scientific Director, QB3@953 & Partner, Mission Bay Capital + more
My goal is to help great startups blossom into successful companies. I helped to set up QB3@953, QB3's newest life-science incubator and I currently direct the QB3@953 core facility and CRO. I am also is a partner at Mission Bay Capital.
Linda McAllister
VP Scientific Affairs, BD Biosciences + more
I am currently VP of Scientific Affairs at BD Biosciences and Chief Medical Officer of Xagentic, Inc. I was previously Chief Medical Officer of CellScape.
Caleb Bell
Founder & CEO, Bell Biosystems + more
I am the Founder and CEO of Bell Biosystems, a synthetic biology company developing living biological tools from a proprietary process that add complex function to cells. I founded Bell BioSystems during my PhD in Biophysical Chemistry at Stanford University.
Ting Jia
Biotech Analyst, BVF Partners + more
I am a biotech analyst at BVF Partners, a private equity firm, looking to invest in all areas of biotechnology sector. Before I was an Engagement Manager at McKinsey & Company for 3 years, specializing in Pharmaceuticals and Medical Products and Private Equity & Principal Investors.
Yumin Choi
HLM Venture Partners + more
I am currently a Director of Vets First Choice and is a board observer at IHM Services and Nordic Consulting, was previously a board observer of TYRX (acquired by Medtronic). I am also a director to The Capital Network, a non-profit focused on educating entrepreneurs around topics of fundraising and finance.
Mark Chin
Vice President, Longitude Capital + more
I work with both the biotechnology and medical technology teams to identify and assess investment opportunities. Prior to joining Longitude Capital in 2012, I was a Consultant at the Boston Consulting Group
Ben Wang
Founder of Svaya Nanotechnologies, Inc. + more
I founded Svaya (svaya-nano.com). Common to the unique. Bad ass surface engineering. I am also a managing partner of 26.2 Ventures LLC where we focus on commercializing technologies for applications in the energy, water, health, and developing nations arenas.
Mary Rozenman
Vice President at Longitude Capital + more
I am a Vice President at Longitude Capital. I focus on investments in biotechnology. Prior to joining Longitude Capital in 2013, I was an Associate Principal at McKinsey & Company and a leader in the Healthcare and Corporate Finance practices. At McKinsey, I served clients in the biotechnology and medical technology industries on a variety of strategic and operational initiatives across commercial operations, research, clinical and corporate development. I also led the support of over $6 billion in healthcare transactions for McKinsey's leading private equity clients.
David Spellmeyer
Chief Technology Officer, Nodality + more
I joined Nodality in 2006. Prior to Nodality, I held positions as a research staff member in the IBM Almaden Services Research group, as chief scientific officer and vice president of drug discovery at Signature BioSciences, as executive director at DuPont Pharmaceuticals, as vice president at CombiChem, and a principal scientist at Chiron.
Remy Durand
Senior Associate, GE Ventures, Healthcare + more
I am a venture capital professional, with a Bioengineering Ph.D., experienced in optogenetics, functional neural imaging, CNS therapeutics, and medical devices.
Bill Martin
Executive Director, Theravance + more
I am an Executive Director in Corporate and Business Development with broad research background that includes CNS and respiratory diseases. I have strong management and leadership experience in small molecule drug discovery and development as well as project selection and research portfolio planning.
Justin Chakma
Associate, Thomas, McNerney & Partners + more
I joined Thomas, McNerney & Partners in 2012, having previously conducted research in support of the Bill and Melinda Gates Foundation. I am a venture capitalist with a focus on building life sciences start-ups. I have experience in investment banking, business development and government innovation policy.
Colleen Cutcliffe
Co-founder & CEO, Whole Biome + more
I am a co-founder and CEO of Whole Biome, a company working with the Mayo Clinic and others to analyze the microbiome, and to develop therapies that use the microbiome to improve human health. Whole Biome, which has been in operation for one year, is a resident company in the Janssen Labs @QB3 space at QB3@953.
Nick Antoniadis
Commercialization Consultant + more
I am a senior strategic marketing leader with 20 years of healthcare experience who delivered on complex global product launches. I have produced award winning strategies that maximize the opportunity at hand with tactics that have been adopted by regional markets around the world.
Kevin Christopher
Industrial Partnerships, Lawrence Livermore National Lab + more
I am a commercialization professional with career interests in open innovation, alliance management, entrepreneurism, and law.
Ravi Kaiwar
Business Development Consultant + more
I have over 20 years of experience in the biopharmaceutical industry with extensive business development, commercial, drug development and R&D experience.
Ruben Rathnasingham
Senior Program Manager, UCSF School of Medicine + more
I am supporting the translation of promising medical research toward clinical relevance. Covering all aspects of healthcare product innovation. I am focusing is on product development, operations, business development and financing in both seed-stage and growth companies. Currently I am supporting the efforts of academic researchers advance their research findings toward clinically beneficial and commercially viable products.
Rick Beberman
Digital Health/Health IT Investment and Corporate Development Professional + more
I have an extensive background in health information technology and digital health. I am currently a member of the advisory board of Trinity Health, an early stage company that has developed a virtual meeting room to assist multidisciplinary medical teams that deliver more effective team-based care. For four year I was a venture associate with Health Care Investment Visions, an organization that invests in seed stage health information tech companies and led business development for one of its portfolio companies. For 15 years, he was an investment banker with No America affiliate of NM Rothschild & Sons and later with Banc of America Securities advising clients on mergers, acquistins, partnerships, and capital raising. He has an MBA from NYU and masters in accounting from USC.
Linda Maxwell
Advisor, Health Venture Services, MaRS Discovery District + more
I am a seasoned health care professional, with over fifteen years of clinical leadership and direct patient care. I have a passion for business, technologic advancement in healthcare and early stage companies, has led me to the nexus of medicine and innovation.
Kevin Webster
Associate, McKinsey & Company + more
I joined McKinsey in 2013 after completing a PhD in Biophysics at UC Berkeley.
Steven Robinette
Associate, McKinsey & Company + more
Steven Robinette is an associate at Atlas and joined in 2015. Previously, Steven was an engagement manager at McKinsey & Company, serving pharmaceutical and biotechnology clients on R&D topics. These topics included R&D investment strategies for a global pharmaceutical company, a platform biotechnology company, and an oncology business unit; single asset diligences in immunology, oncology, and CNS/pain; and post-acquisition integration of R&D organizations.
Vikram Ranade
Associate, McKinsey & Company + more
I joined McKinsey in 2013 after completing a Ph.D. in Genetics at Columbia University.
Ruth Wexler
Executive Director at Bristol-Myers Squibb + more
Dr. Ruth Wexler joined the Bristol-Myers Squibb Company as Executive Director, Discovery Chemistry, (post-acquisition of DuPont Pharmaceuticals Company) and in the fall of 2002, she moved to Hopewell site in New Jersey where she currently heads the medicinal chemistry efforts directed at Cardiovascular Diseases. She was honored in 2004 as one of twelve Outstanding New Jersey Women in Research by the New Jersey Association for Biomedical Research. In 2011, she was a recipient of the Bristol-Myers Squibb Ondetti and Cushman award for her leadership role in the discovery of Eliquis®. She has been selected as the recipient of the 2015 E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances. Ruth has co-authored over 190 peer-reviewed scientific publications and patents, and has contributed several review articles and book chapters largely in the area of cardiovascular research.
Europe Mentors
Deborah Harland
Partner, SR One + more
I joined SR One in 2005 to establish the firm's European investment office. I have extensive operational, drug development and licensing experience gained through numerous roles held in clinical development, medical affairs and business development during more than 20 year tenure in the pharmaceutical industry. I am currently a member of the Board of Directors of Mission Therapeutics, Bicycle Therapeutics, Atopix Therapeutics, AtoxBio, f-star and VH Squared.
Matthew Foy
Partner, SR One + more
I joined SR One in 2011 to take the lead in investing SR One's UK biotech fund. Prior to joining SR One I worked as a consultant for Longbow Capital Partners in London, and before that I was a Vice President of Greenhill & Co, an M&A Investment Bank and Private Equity firm.
Matthias Essenpreis
Chief Technology Officer, Roche Diagnostics + more
I am the Chief Technology Officer, Diagnostics at F. Hoffmann-La Roche Ltd. Prior to that, I was the Head Global Research and Technology of Roche Diabetes Care.
Claire Brown
Investment Manager, Alderley Park Ventures + more
I manage a life science focused seed fund leading the identification, evaluation & diligence on opportunities for investment (devices, products and platform technologies) having previously, at AstraZeneca, led all aspects of in-licensing business development activities from ‘search and evaluate’ to delivery of business case proposals.
Nooman Haque
Director of Life Sciences, Silicon Valley Bank + more
I lead the European life science & healthcare business at Silicon Valley Bank, supporting early and late stage companies with their financing needs. We work across all sub-sectors including biotech, medtech, and digital health.
Alan Ashby
VP, Global Concept Development, DePuy - a Johnson & Johnson Company + more
I am VP of Global Concept Development at DePuy Synthes, a Johnson & Johnson Company and and global leaders in providing healthcare solutions in orthopaedics, spinal care, sports medicine and neurosciences.
David Phillips
Partner, SR One + more
I joined SR One in 2008 to pioneer a new function to incubate and spin-out technologies from GSK and subsequently joined the team focusing on European investments. I bring a range of experience to SR One, including senior management roles in sales and marketing, commercial strategy and business development at Glaxo Wellcome, Cephalon, Medical Venture Management, The Automation Partnership and Galapagos. I have significant deal making experience in the pharmaceutical and biotech sectors and has run a number of successful businesses deriving healthy exits for investors.
Daniel Janse
Senior Director, New Ventures, Johnson & Johnson Innovation, London + more
I am Senior Director of New Ventures at Johnson & Johnson Innovation, London. Previously, I was an Investment Manager at Inventages, the strategic investment arm of Nestlé, where I evaluated mid-stage opportunities for therapeutics, medical devices, diagnostics and consumer healthcare.
Declan Jones
VP Neuroscience Scientific Innovation, Johnson & Johnson Innovation London + more
I am Vice President of Neuroscience Scientific Innovation at Johnson & Johnson Innovation London. I previously worked for GSK’s Centre of Excellence for External Drug Discovery (CEEDD) where I was responsible for creating scientific strategies and managing processes from preclinical to Phase II state programs across all therapeutic areas.
Elena Fernandez-Kleinlein
Senior Director, Consumer Scientific Innovation, Johnson & Johnson Innovation, London + more
I am Senior Director of Consumer Scientific Innovation at Johnson & Johnson Innovation, London. Previously as Senior Director of R&D Global Topical Health Care for Johnson & Johnson Consumer & Personal Products, I was responsible for seeking innovative products and claims pipelines within the franchise and oversaw the product development program for iconic brands such as Band-Aid Adhesive Bandages, Johnson & Johnson’s Red Cross and other regional brands like Compeed, Neosporin and Bengay.
Johan Verbeeck
Senior Director, Partnership Management, Johnson & Johnson Innovation, London + more
I am Senior Director of Partnership Management at Johnson & Johnson Innovation, London. Previously, I was Director of Toxicology at Tibotec where I worked on the development of Prezista and Intelence, Tibotec’s first two approved anti-HIV drugs. After the approval of Intelence, I transferred to North America to become Head of Toxicology Sciences for Janssen at the Raritan, NJ site.
Karin Conde-Knape
Vice President of Cardiovascular & Metabolic Scientific Innovation, Johnson & Johnson Innovation, London + more
I am VP Cardiovascular & Metabolic Scientific Innovation at Johnson & Johnson Innovation, London. Previously, I was Global Head of Discovery in the CVM DTA at Roche where I was responsible for all the Early Research efforts as well as the Translational Biomarker and experimental medicine group. While at Roche, I was responsible for identifying and managing numerous external collaborations with well renowned institutions worldwide.
Kurt Hertogs
Platform Innovation & Incubator Strategy Leader, Johnson & Johnson Innovation, London. + more
I am Platform Innovation & Incubator Strategy Leader at Johnson & Johnson Innovation, London. Previously, I held research and early stage development roles at Tibotec and was involved in the discovery and pharmacological profiling of major anti-infective drugs like Prezista, Intellence, Edurant, Incivo and Simeprevir.
Roger Bone
Vice President of Transactions, Johnson & Johnson Innovation, London + more
I am Vice President of Transactions at Johnson & Johnson Innovation, London. Prior to this role, Roger was Vice President Scientific Affairs within New Ventures business development. I was formerly Global Head, Research Capabilities with responsibility for chemistry and enabling technologies supporting therapeutic area discovery efforts.
Yelda Kaya
Senior Director Transactions, Johnson & Johnson Innovation, London + more
I have an extensive background in life sciences with previous roles in worldwide business development at GSK, as a corporate lawyer and emergency medicine clinician.
Michal Silverberg
Senior Director, External Innovation, Takeda Ventures + more
Currently based in Israel, I joined TVI in September 2014 as Senior Director for External Innovation with a primary focus on Israel and Europe. Since 1998, I have held positions in various sectors of the life science industry including in the Office of the Chief Scientist of Israel (The Incubator program), venture capital (Ofer Brothers Hi Tech) and global pharmaceutical and biotech companies.
Chris Brown
Director, Worldwide Business Development, GSK + more
I joined GSK as Director, Worldwide Business Development in 2011. Prior to that I was Director, Worldwide Business Development at Pfizer.
Rick Cousins
Senior Director, Alternative Discovery & Development, GSK + more
I am leading the creation of a new pre-Discovery Performance Unit (DPU) at GSK hearing disorders within the Alternative Discovery & Development organisation at Stevenage. I have been involved in programmes at all stages of drug discovery on a wide variety of targets for many therapeutic areas including anti-virals, anti-fungals, cardiovascular, respiratory, inflammation, neurology and metabolism.
Veronique Birault
Director, Respiratory Therapeutic Area, GSK + more
I have 14 years of pharmaceutical drug discovery and development experience. I am a medicinal chemist by training with experience in developing molecules and antibodies from discovery through clinical development mainly in immuno-inflammation and respiratory diseases. Prior to GSK, I spent 6 years at BioFocus DPI, a UK based CRO providing research to the pharmaceutical industry. During my career I have led multidisciplinary teams / unit (with medicinal chemists, biologists, physicians and pharmacologists) , lead academic/ industry drug discovery collaborations, define strategies and deliver success.
A. Maria Dahl
Executive Business Development Director, AstraZeneca + more
My responsibilities are for negotiating oncology licensing and collaboration agreements. I have more than 12 years experience in business development and portfolio management from the US and UK pharmaceutical and biotech industry. I have also been a non-executive director on the board of a private UK biotech company, and also previously co-chaired or been a jury member in US and French business plan competitions.
Simon Hollingsworth
Executive Director, Oncology Innovative Medicines & Early Development, AstraZeneca + more
I'm responsible for development and delivery of AstraZeneca’s portfolio of Stratified Medicine Studies, partnered Stratified Medicine initiatives (National, European, US, Asia) and basket studies, and Senior Project Director in Oncology Early Clinical Development. I have >20 years experience in drug and therapeutics development across industry (AstraZeneca, Roche/Genentech) and academic (University College London, King’s College London) careers focused in clinical and translational science, and personalised healthcare in oncology, inflammation and cardio-/vascular fields.
Lynne Murray
Associate Director, Partnering & Strategy, MedImmune + more
After joining MedImmune, I initially focused on the fibrosis research efforts, both internally and with external collaborators and have since gained an MBA. I'm now Partnering & Strategy group at MedImmune and my research interests span the underlying pathways promoting the effects of injury, inflammation and I have successfully transitioned 3 therapeutics into Ph2.
Joseph Smart
Vice President, Silicon Valley Bank + more
I am responsible for the financial analysis, structuring and management of debt relationships in addition to commercial banking and cash management solutions for a portfolio of early and growth stage technology companies.
Pierre Socha
Investment Manager, Amadeus Capital Partners + more
I focus on the medtech and healthcare IT sectors and bring operational experience to the portfolios of Amadeus, having grown and turned around several life science and cleantech companies in Asia, Europe and the Americas. Over a decade with Avesthagen Ltd, I guided the group’s global strategy and European activities, raised US $120 million and led two dozen transactions including acquisitions, joint-ventures and exits.
Allan Marchington
Partner, Apposite Capital + more
I am in charge of Apposite's Life Sciences investments. A founding member at Apposite, I am a proven entrepreneur and executive in the pharmaceuticals sector and currently sit on the Board of the UK BioIndustry Association.
Barbara Domayne-Hayman
Chief Business Officer, Autifony Therapeutics + more
I am a company builder and deal-maker in biotech, who has successfully transitioned from working in large organisations to an entrepreneurial environment and mindset. I want to make a real contribution to society through the commercialisation of new science. I also have a passion for opera and playing the harp and piano.
Lionel Carnot
Managing Director, Bay City Capital LLC + more
I have been extensively involved in the firm’s activities since I joined The Pritzker Organization in 2000. I manage the firm’s investments in Europe. Prior to The Pritzker Organization, I was a Principal at Oracle Partners, a healthcare hedge fund. I also held several positions in the pharmaceutical industry, including Product Manager for Prozac at Eli Lilly as well as several sales and marketing positions at Aventis.
Davidson Ateh
CEO, BioMoti + more
I am a co-inventor of the Oncojan™ platform and CEO of BioMoti, leading on operations, product and business development activities with my interdisciplinary scientific background in the physical and life sciences. I have a successful track record of financing disruptive ideas, progressing projects and gaining awards.
John Beadle
CEO, PsiOxus Therapeutics + more
I am an entrepreneur with a strong medical and business background. In 2010, my leadership of Myotec Therapeutics and Hybrid Biosystems led to their combination to form PsiOxus Therapeutics Ltd.
Will West
President & CEO, Cancer Targeting Systems (CTS) Inc. + more
I am a biotechnology chief executive, with experience spanning basic research through to late stage clinical trials (biotech, pharma/corporate, public funding body).
Neill Moray Mackenzie
CBO, Biotecnol Ltd; Chairman, Cellular Therapeutics Ltd; CEO Trimunocor Ltd + more
I am internationally networked pharmaceutical executive and a serial entrepreneur with extensive operational, commercial, licensing and R&D background in academia, pharma and biotech companies. After completing my PhD in immunology and post‐doctoral work at the National Institute for Medical Research with the MRC, I became the Wellcome Trust lecturer in immunology in the University of London. I joined Wellcome plc as Head of the Immunology and Anti-infectives Department continuing with Mallinckrodt Inc. after it acquired the Division. Over the last nineteen years, I have served on the Boards of biotech companies in the immunology and immune-oncology space. Serving in Trimunocor Ltd as founder and CEO (current), Biotecnol Ltd as CBO (current), Cellular Therapeutics Ltd as a non-exec director (current), CMP Therapeutics Ltd as CEO, Roji Ltd as founder and CEO, Medigene AG (listed on the German Börse) as SVP Business Development and Commercial Strategy, Avidex Ltd, as CBO, Oxford BioMedica plc (listed on the LSE), and BioMedica Inc as co-founder and EVP of Business development and Corporate Strategy and with Cambridge Genetics Ltd., I was the co-founder and CEO. In these companies I took primary responsibility all elements of corporate business development, including M&A, partnering, licensing, PR and IR. As an Executive Director with P&L responsibilities, in listed (both the full London Stock Exchange (LSE) and the Alternative Investment Market) and private companies he has raised over $150 million equity capital from private and public funds and completed numerous deals with pharmaceutical companies globally.
Fiona Marshall
Co-founder & CSO, Heptares Therapeutics + more
I am a founder and Chief Scientific Officer of the Heptares Therapeutics a Drug discovery and development company. I previously acted as a consultant to a range of Venture Capital companies advising on start up opportunities. Prior to that I worked as Director of Biology at Millenium Pharmaceuticals and Director of Molecular Pharmacology at GlaxoWellcome.
Charles MacKinnon
Director, Greater Manchester Academic Health Science Network + more
AHSNs present a unique opportunity to pull together the adoption and spread of innovation with clinical research and trials, informatics, education, and healthcare delivery. I'm helping to build strong relationships between regional scientific and academic communities and industry.
Michelle Scott
Biologics Solution Director, Covance + more
I am an experienced senior business leader and biological medicines development expert with a unique combination of strategic, business development, regulatory affairs, scientific and management expertise gained in the biopharmaceutical sector.
Inga Deakin
Healthcare Ventures Associate, Imperial Innovations + more
I specialise in investments across medical devices, therapeutics, diagnostics, and healthcare, including digital health.
Jonathan Tobin
Associate, Healthcare Ventures at Imperial Innovations + more
I am a life science specialist with experience of early and later stage venture capital deals, specialised in therapeutics and diagnostics. Board director of two specialist diagnostics companies, board observer of two therapeutics companies.
Kathryn Owen
Healthcare Ventures Associate, Imperial Innovations + more
I focus on investments into early stage therapeutics and diagnostic opportunities from first-class research institutions within the Oxford-London-Cambridge triangle.
Rob Woodman
Healthcare Ventures Director, Imperial Innovations + more
I currently serve on the board of Mission Therapeutics, Stanmore Implants, and Nascient Therapeutics. I was previously Principal in the life science team at Sofinnova Partners, a leading European venture capital firm.
Mark Phillips
Executive advisor to biotech and healthtech companies + more
I am a senior executive with over 30 years experience in the pharmaceutical, diagnostics and life sciences industries. I have led global teams in research and development, and in manufacturing to create new businesses and transform performance. I am passionate about building new capabilities in teams and individuals (through coaching), and working with smaller businesses and academia to translate ideas and strategy into products and results.
Itxaso Del Palacio
Investment Director, Lepe Partners + more
At Lepe Partners, I am responsible for the DD and execution of investments. Prior to that, I was at EC1 Capital to build quality deal flow and support portfolio companies with specific needs. I have worked with entrepreneurs coming from universities in Silicon Valley (UC Berkeley), Spain (UPC, UPF) and now in London (Imperial College and UCL). As an academic, I am a Teaching Fellow in Entrepreneurship at UCL.
Nicholas Edwards
Chairman of MedInnovate, Kinapse & Oxtex + more
I am a medically qualified doctor with 25 years experience of consulting, with a particular focus on healthcare, life sciences and pharmaceuticals. I work with large pharmaceutical companies, regulatory bodies, start up and small businesses in the healthcare, pharmaceutical, biotechnology medical or diagnostic devices area. I am interested in supporting the rapid translation of medical innovations into commercially successful businesses, including technology transfer from universities to spin outs.
Dan Vàhdat
CTO & Co-founder, Medopad + more
I drive product vision, technology and strategy of Medopad. I am an award winning innovator in the fields of science and technology. My professional career spans from IT to medical technology including two years at Johns Hopkins in the US. I studied Engineering and Mathematics, after which I pursued my PhD in Bio-Engineering at Johns Hopkins and Oxford University.
Andy Sandham
Partner, Syncona Partners + more
I am a Partner of Syncona Partners LLP. Previously I was a co-founder, Chairman and CEO of Kymab. I have played a key role in building successful businesses in pharmaceutical discovery and development in Europe and the USA, serving as a founder and executive of Cantab Pharmaceuticals, Hexagen, Signature BioScience and Ionix Pharmaceuticals.
Hakan Goker
Investment Director, MS Ventures + more
I am a private biotechnology and medtech investor instrumental in the formation, management and business strategy of new companies, currently a director at MS Ventures, and previously a partner at Aescap Venture, with experience from Atlas Venture and postdoctoral molecular biology training.
Sara Núñez-Garcia
Senior Associate, Sofinnova Partners + more
Sara Núñez García joined the Life Sciences team as an Associate in 2013; Sara focuses on investments in the biopharmaceutical sector. Prior to Sofinnova Partners, Sara worked in the Licensing and M&A team at Onyx Pharmaceuticals in California, where she proposed option-based and structured deals for various potential acquisitions in the oncology space. Previously, Sara spent six years in the pharmaceutical industry with Solvay and Abbott Laboratories in The Netherlands as a Medicinal Chemist. During her time in drug discovery, Sara worked on preclinical programmes for central nervous system indications, contributing to the submission of several IND packages of novel chemical entities. In addition, Sara led transfer-of-knowledge projects with several universities in Amsterdam. Sara was a postdoctoral fellow in the Biochemistry and Biophysics departments at the Albert Einstein College of Medicine in New York where she developed inhibitors for oncology targets. She has a PhD in Chemistry from the University of Manchester; her doctoral research used a combination of experimental and computational techniques to design and synthesize transition state inhibitors. Sara has published eighteen peer-reviewed articles and patents. Sara also holds an MBA from INSEAD (finance major).
Rachel Moss
Associate Principal, Pharmaceutical and Medical Products Practice, McKinsey & Company + more
I joined McKinsey after completing a postdoctoral fellowship at Columbia University Medical Center following my PhD in Neuroscience at King's College London.
Shane Gannon
Consultant, McKinsey & Company + more
I am an Associate in the UK/Ireland office. Since joining McKinsey in 2012, I have mainly worked in the pharmaceutical and healthcare sectors covering topics such as M&A, quality assurance, sourcing, operations and transformational change.
Veronique Bouchet
Founder, Novudel Associates + more
I have over 25 years international experience in the healthcare industry. I founded Novudel Associates, a life sciences consulting and coaching company, and I am also a non-executive director of the Stevenage Bioscience Catalyst and of International Biotechnology Trust plc.
Brewster Barclay
Business Development Director, Zuhlke Engineering + more
I have 20+ years high-tech industry experience in software and manufacturing. I'm passionate about technology and introducing new products and services to markets that have never existed before.
Daniel Swann
Associate, McKinsey & Company + more
I am a junior project manager (JEM) with a focus on strategy & commercial topics in the healthcare, pharmaceuticals & medical devices industries.
Julius Bruch
Associate, McKinsey & Company + more
I joined McKinsey in 2014, after working on clinical trials for neurodegenerative diseases and undertaking research on PSP pathogenesis at the German Centre for Neurodegenerative Disease Research.
Thomas Saylor
Non-executive Director, Arecor Limited + more
I have served as CEO of several emerging biotech companies both in Europe and Asia. Most recently I was as CEO of Arecor Limited, a British company focused upon enabling the next generation of therapeutic proteins and vaccines through advanced formulation technologies. Previously, I was CEO of Sirus Limited, a drug targeting and delivery company based in Cambridge, England. Prior to joining Sirus, I was Chairman and founder of Lotus Healthcare Corporation, an Asian-based fully integrated pharmaceutical company. I am also actively involved in development of public policies as Chairman of the SME Platform and Vice-Chairman and a member of the board of EuropaBio, and serve on the scientific advisory boards of several universities.
Charles MacKinnon
Director, Integro Care Solutions + more
Integro Care Solutions provides citizen centred assessment and delivery of personalised support to improve the health outcomes of populations. We do this by developing cloud-based software solutions for assessing, co-ordinating, managing and monitoring the provision of patient care and assisted living support around the needs of the individual.